Cargando…
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
BACKGROUND: Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. METHODS: In this multicenter, prospective, observational study of adults treated with MEC whi...
Autores principales: | Matsui, Reiko, Suzuki, Kenichi, Takiguchi, Tomomi, Nishio, Makoto, Koike, Takeshi, Hayashi, Toshinobu, Seto, Takashi, Kogure, Yuki, Nogami, Naoyuki, Fujiwara, Kimiko, Kaneda, Hiroyasu, Harada, Tomohiko, Shimizu, Satoru, Kimura, Masashi, Kenmotsu, Hirotsugu, Shimokawa, Mototsugu, Goto, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539512/ https://www.ncbi.nlm.nih.gov/pubmed/33023657 http://dx.doi.org/10.1186/s40360-020-00445-y |
Ejemplares similares
-
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk
por: Shimokawa, Mototsugu, et al.
Publicado: (2021) -
Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study
por: Hayashi, Toshinobu, et al.
Publicado: (2018) -
Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022) -
A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin‐Based Chemotherapy‐Induced Nausea and Vomiting in Japan
por: Iihara, Hirotoshi, et al.
Publicado: (2019) -
Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
por: Iihara, Hirotoshi, et al.
Publicado: (2016)